Enfusion Inc (NYSE:ENFN) Receives $18.60 Consensus Target Price from Brokerages

Shares of Enfusion Inc (NYSE:ENFNGet Rating) have been given an average recommendation of “Hold” by the eight analysts that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $18.60.

ENFN has been the subject of several recent research reports. Zacks Investment Research raised shares of Enfusion from a “sell” rating to a “hold” rating in a research report on Thursday. Credit Suisse Group dropped their price objective on shares of Enfusion from $25.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, March 25th. The Goldman Sachs Group dropped their price objective on shares of Enfusion from $24.00 to $15.00 and set a “neutral” rating for the company in a research report on Wednesday, March 16th. Morgan Stanley dropped their price objective on shares of Enfusion from $22.00 to $18.00 and set an “equal weight” rating for the company in a research report on Friday, March 25th. Finally, Piper Sandler dropped their price objective on shares of Enfusion from $26.00 to $20.00 in a research report on Friday, March 25th.

Several hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Enfusion in the fourth quarter valued at $10,379,000. BlackRock Inc. bought a new position in Enfusion during the 4th quarter valued at $27,071,000. Wells Fargo & Company MN bought a new position in Enfusion during the 4th quarter valued at $669,000. Woodline Partners LP bought a new position in Enfusion during the 4th quarter valued at $524,000. Finally, Nellore Capital Management LLC bought a new position in Enfusion during the 4th quarter valued at $1,047,000. Institutional investors and hedge funds own 2.29% of the company’s stock.

Shares of ENFN stock opened at $11.41 on Thursday. Enfusion has a one year low of $10.29 and a one year high of $23.21. The stock’s 50 day moving average is $14.30.

Enfusion (NYSE:ENFNGet Rating) last issued its quarterly earnings results on Thursday, March 24th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Equities research analysts expect that Enfusion will post 0.22 EPS for the current fiscal year.

About Enfusion (Get Rating)

Enfusion Inc is a provider of cloud-based investment management software and services. Through its software, analytics and middle/back-office managed services, it creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion Inc is based in NEW YORK.

Featured Stories

Analyst Recommendations for Enfusion (NYSE:ENFN)

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.